Eli Lilly presented Phase IIb data for a combination of the amylin agonist eloralintide plus tirzepatide (Zepbound) in obese patients with type 2 diabetes, reporting weight loss of 23.3% at the highest dose after 48 weeks. Lilly framed the results as a further differentiation within its amylin race, highlighting performance in a harder diabetic obesity population. The company’s update is notable because earlier obesity programs have struggled with diabetic populations where glycemic control and metabolic comorbidities can complicate weight-loss durability. Phase IIb readouts are also being used by investors as a proxy for which combinations can maintain meaningful losses as companies compete for positioning ahead of late-stage trials. For biotech strategists, the competitive message is that multi-hormone approaches are being stress-tested across increasingly specific patient segments, not only broad obesity cohorts. The next inflection point will be the translation of Phase IIb outcomes into late-stage efficacy and safety packages. (Selected item reflects the Phase IIb presentation and combination context.)